Refractory anemia with excess of blasts: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{Infobox medical condition | |||
| name = Refractory anemia with excess of blasts | |||
| synonyms = RAEB | |||
| field = [[Hematology]] | |||
| symptoms = [[Anemia]], [[fatigue]], [[pallor]], [[dyspnea]], [[bruising]], [[bleeding]] | |||
| complications = Progression to [[acute myeloid leukemia]] | |||
| onset = Typically in older adults | |||
| duration = Chronic | |||
| causes = [[Myelodysplastic syndrome]] | |||
| risks = [[Age]], [[previous chemotherapy]], [[radiation therapy]], [[genetic predisposition]] | |||
| diagnosis = [[Bone marrow biopsy]], [[blood tests]] | |||
| differential = [[Aplastic anemia]], [[acute myeloid leukemia]], [[other myelodysplastic syndromes]] | |||
| treatment = [[Supportive care]], [[blood transfusions]], [[chemotherapy]], [[stem cell transplant]] | |||
| prognosis = Variable, depends on progression to leukemia | |||
| frequency = Rare | |||
}} | |||
'''Refractory anemia with excess of blasts''' (RAEB) is a type of [[myelodysplastic syndrome]] (MDS), a group of diseases in which the bone marrow does not make enough healthy blood cells. RAEB is characterized by the presence of too many immature blood cells (blasts) in the bone marrow and blood, and too few healthy blood cells in the body. | '''Refractory anemia with excess of blasts''' (RAEB) is a type of [[myelodysplastic syndrome]] (MDS), a group of diseases in which the bone marrow does not make enough healthy blood cells. RAEB is characterized by the presence of too many immature blood cells (blasts) in the bone marrow and blood, and too few healthy blood cells in the body. | ||
== Classification == | == Classification == | ||
RAEB is further classified into two subtypes: RAEB-1 and RAEB-2, based on the percentage of blasts in the bone marrow and blood. This classification is done according to the [[World Health Organization]] (WHO) criteria. | RAEB is further classified into two subtypes: RAEB-1 and RAEB-2, based on the percentage of blasts in the bone marrow and blood. This classification is done according to the [[World Health Organization]] (WHO) criteria. | ||
== Symptoms == | == Symptoms == | ||
Patients with RAEB may experience symptoms such as fatigue, shortness of breath, easy bruising or bleeding, and increased risk of infections due to a decrease in healthy blood cells. Some patients may not have any symptoms at the time of diagnosis and the disease may be discovered during routine blood tests. | Patients with RAEB may experience symptoms such as fatigue, shortness of breath, easy bruising or bleeding, and increased risk of infections due to a decrease in healthy blood cells. Some patients may not have any symptoms at the time of diagnosis and the disease may be discovered during routine blood tests. | ||
== Diagnosis == | == Diagnosis == | ||
Diagnosis of RAEB is based on blood tests, bone marrow examination, and cytogenetic analysis. The [[Complete blood count]] (CBC) may show low levels of red blood cells, white blood cells, and platelets. Bone marrow examination reveals an excess of blasts. Cytogenetic analysis can identify specific genetic changes that are associated with RAEB. | Diagnosis of RAEB is based on blood tests, bone marrow examination, and cytogenetic analysis. The [[Complete blood count]] (CBC) may show low levels of red blood cells, white blood cells, and platelets. Bone marrow examination reveals an excess of blasts. Cytogenetic analysis can identify specific genetic changes that are associated with RAEB. | ||
== Treatment == | == Treatment == | ||
Treatment for RAEB is aimed at reducing the symptoms, improving quality of life, and extending survival. Treatment options may include supportive care, drug therapy, and stem cell transplantation. The choice of treatment depends on various factors such as the patient's age, overall health, and the specific characteristics of the disease. | Treatment for RAEB is aimed at reducing the symptoms, improving quality of life, and extending survival. Treatment options may include supportive care, drug therapy, and stem cell transplantation. The choice of treatment depends on various factors such as the patient's age, overall health, and the specific characteristics of the disease. | ||
== Prognosis == | == Prognosis == | ||
The prognosis for patients with RAEB varies widely and depends on several factors, including the subtype of RAEB, the patient's age and overall health, and the specific genetic changes present in the disease. | The prognosis for patients with RAEB varies widely and depends on several factors, including the subtype of RAEB, the patient's age and overall health, and the specific genetic changes present in the disease. | ||
== See also == | == See also == | ||
* [[Myelodysplastic syndrome]] | * [[Myelodysplastic syndrome]] | ||
| Line 26: | Line 32: | ||
* [[Complete blood count]] | * [[Complete blood count]] | ||
* [[World Health Organization]] | * [[World Health Organization]] | ||
[[Category:Myelodysplastic syndromes]] | [[Category:Myelodysplastic syndromes]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
{{Hematology-stub}} | {{Hematology-stub}} | ||
{{Medicine-stub}} | {{Medicine-stub}} | ||
Latest revision as of 04:12, 4 April 2025
| Refractory anemia with excess of blasts | |
|---|---|
| Synonyms | RAEB |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Anemia, fatigue, pallor, dyspnea, bruising, bleeding |
| Complications | Progression to acute myeloid leukemia |
| Onset | Typically in older adults |
| Duration | Chronic |
| Types | N/A |
| Causes | Myelodysplastic syndrome |
| Risks | Age, previous chemotherapy, radiation therapy, genetic predisposition |
| Diagnosis | Bone marrow biopsy, blood tests |
| Differential diagnosis | Aplastic anemia, acute myeloid leukemia, other myelodysplastic syndromes |
| Prevention | N/A |
| Treatment | Supportive care, blood transfusions, chemotherapy, stem cell transplant |
| Medication | N/A |
| Prognosis | Variable, depends on progression to leukemia |
| Frequency | Rare |
| Deaths | N/A |
Refractory anemia with excess of blasts (RAEB) is a type of myelodysplastic syndrome (MDS), a group of diseases in which the bone marrow does not make enough healthy blood cells. RAEB is characterized by the presence of too many immature blood cells (blasts) in the bone marrow and blood, and too few healthy blood cells in the body.
Classification[edit]
RAEB is further classified into two subtypes: RAEB-1 and RAEB-2, based on the percentage of blasts in the bone marrow and blood. This classification is done according to the World Health Organization (WHO) criteria.
Symptoms[edit]
Patients with RAEB may experience symptoms such as fatigue, shortness of breath, easy bruising or bleeding, and increased risk of infections due to a decrease in healthy blood cells. Some patients may not have any symptoms at the time of diagnosis and the disease may be discovered during routine blood tests.
Diagnosis[edit]
Diagnosis of RAEB is based on blood tests, bone marrow examination, and cytogenetic analysis. The Complete blood count (CBC) may show low levels of red blood cells, white blood cells, and platelets. Bone marrow examination reveals an excess of blasts. Cytogenetic analysis can identify specific genetic changes that are associated with RAEB.
Treatment[edit]
Treatment for RAEB is aimed at reducing the symptoms, improving quality of life, and extending survival. Treatment options may include supportive care, drug therapy, and stem cell transplantation. The choice of treatment depends on various factors such as the patient's age, overall health, and the specific characteristics of the disease.
Prognosis[edit]
The prognosis for patients with RAEB varies widely and depends on several factors, including the subtype of RAEB, the patient's age and overall health, and the specific genetic changes present in the disease.
See also[edit]
This article is a hematology stub. You can help WikiMD by expanding it!
